Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invicta DiagnosticNSE:INVICTA +3.88%21 Days Payable is 393.85 as of Mar. 2026, which is 154% above its 10-year median of 155.32. GuruFocus rates NSE:INVICTA with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 189 Medical Diagnostics & Research companies, Invicta Diagnostic ranks better than 83.6% on this metric.
The historical rank and industry rank for Invicta Diagnostic's Days Payable or its related term are showing as below:
NSE:INVICTA'
s Days Payable Range Over the Past 10 Years
Min: 155.21 Med: 155.32 Max: 473.65
Current: 283.69
During the past 3 years, Invicta Diagnostic's highest Days Payable was 473.65. The lowest was 155.21. And the median was 155.32.
NSE:INVICTA's Days Payable is ranked better than 83.6% of 189
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.92
vs NSE:INVICTA: 283.69
Invicta Diagnostic's Days Payable
increased
from Mar. 2025 (0.00) to Mar. 2026 (393.85).
It may suggest that Invicta Diagnosticdelayed paying its suppliers.
The historical data trend for Invicta Diagnostic's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic Days Payable Chart
Invicta Diagnostic Annual Data
Trend
Mar24
Mar25
Mar26
Days Payable
473.65
155.32
155.21
Invicta Diagnostic Semi-Annual Data
Mar24
Mar25
Sep25
Mar26
Days Payable
0.00
0.00
301.11
393.85
NSE:INVICTA vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Invicta Diagnostic's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invicta Diagnostic Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invicta Diagnostic's Days Payable distribution charts can be found below:
* The bar in red indicates where Invicta Diagnostic's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Invicta Diagnostic's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic (NSE:INVICTA) has a Days Payable of 393.85 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Invicta Diagnostic and its competitors. This is 154% above median its historical median of 155.32. Over the past decade, Invicta Diagnostic's Days Payable has ranged from 155.21 to 473.65. According to the industry distribution chart, Invicta Diagnostic ranks #31 out of 189 companies in the Medical Diagnostics & Research industry, placing it in the top 16.4%.
Is Invicta Diagnostic's Days Payable too high?
Invicta Diagnostic's current Days Payable of 393.85 is 154% above median its 10-year median of 155.32. Over the past 10 years, this metric has ranged from a low of 155.21 to a high of 473.65. The Medical Diagnostics & Research industry median Days Payable is 64.92. Invicta Diagnostic's value of 393.85 is 506.7% above this industry median. Based on the distribution chart, Invicta Diagnostic ranks #31 out of 189 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Invicta Diagnostic has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Invicta Diagnostic ranks #31 out of 189 companies for Days Payable. This places Invicta Diagnostic in the top 16% of its industry — outperforming the majority of peers. The industry median Days Payable is 64.92. Invicta Diagnostic's value of 393.85 is 506.7% above this benchmark. Historically, Invicta Diagnostic's own Days Payable has ranged from 155.21 to 473.65 over the past decade. While the company's 10-year median is 155.32 vs. the industry median of 64.92, Invicta Diagnostic has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.92, based on 189 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invicta Diagnostic's current Days Payable of 393.85 is 506.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Invicta Diagnostic and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invicta Diagnostic's current Days Payable is 393.85, which is 154% above median its own 10-year median of 155.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current Days Payable of 393.85. The current Days Payable is 393.85, which is 154% above median its 10-year median of 155.32 and 506.7% above the Medical Diagnostics & Research industry median of 64.92. Invicta Diagnostic's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current Days Payable is 393.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
21GF Score
Get the complete analysis for NSE:INVICTA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INVICTA has been successfully added to your 
